03:33 PM EST - Aeterna Zentaris Inc. : Announced that the independent Data and Safety Monitoring Board has recommended that the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, continue as planned. Aeterna Zentaris Inc.
shares T.AEZ are trading down $0.015 at $0.10.
